Bifidobacterium longum 35624 vs De Simone Formulation
How Bifidobacterium longum 35624 and De Simone Formulation differ in how they work, evidence, tolerance, and cost.
This page contains affiliate links. Titrate earns a small commission when you purchase through them, at no cost to you. This does not affect our recommendations.
Side by Side
| Bifidobacterium longum 35624 | De Simone Formulation (8 strains) | |
|---|---|---|
| How it works | Acts in the gut lumen. In the main IBS trial, 100 million CFU improved symptoms and 10 billion CFU did not, likely because the high-dose capsule formulation clumped. | High-dose mix of eight lactobacillus, bifidobacterium, and Streptococcus thermophilus strains; acts in the lumen of the colon. |
| Typical dose | 100 million CFU daily | 450-1,800 billion CFU daily (pouchitis) |
| Common uses | IBS | pouchitis, ulcerative colitis (adjunct) |
| Side effects | Bloating. | Bloating. |
| Cost | Moderate | High |
| Also called | Align, B. infantis 35624 | Visbiome, original VSL#3 formula |
When to Choose Bifidobacterium longum 35624
Choose Bifidobacterium longum 35624 when you have IBS and want a strain with a large trial. Proof that higher CFU is not automatically better.
Bifidobacterium longum 35624
One large IBS trial at a low dose. A good illustration that more CFU is not the goal.
What to look for: B. longum 35624 (Align), one capsule daily for at least four weeks.
Find on iHerb Affiliate linkWhen to Choose De Simone Formulation (8 strains)
Choose De Simone Formulation when you have pouchitis or ulcerative colitis and your gastroenterologist recommends it. Since 2016 the original formula has been sold as Visbiome; products sold as VSL#3 after that date come from a different manufacturer.
De Simone Formulation (8 strains)
High dose and high cost, for pouchitis and some ulcerative colitis. Not a general-purpose product.
What to look for: Visbiome (the original De Simone formula), at the dose your gastroenterologist sets.
Find on iHerb Affiliate linkProducts on Titrate
The Probiotics category in Titrate's index holds 5,145 labels from the NIH Dietary Supplement Label Database, 2,852 of them currently on market, out of 214,745 labels indexed in total.
Supplement Search loads one category at a time. Choose the Probiotics tab and filter by ingredient, form, or what the product leaves out.
Related
References
NIH Office of Dietary Supplements. Probiotics: Fact Sheet for Health Professionals.
Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119(2):305-309.
Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101(7):1581-1590.
Hill C, Guarner F, Reid G, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506-514.
Szajewska H, Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2015;42(7):793-801.
Goldenberg JZ, Yap C, Lytvyn L, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017;12(12):CD006095.
Suez J, Zmora N, Zilberman-Schapira G, et al. Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell. 2018;174(6):1406-1423.
Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48(10):1044-1060.
Guo Q, Goldenberg JZ, Humphrey C, El Dib R, Johnston BC. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2019;4(4):CD004827.
Su GL, Ko CW, Bercik P, et al. AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders. Gastroenterology. 2020;159(2):697-705.